BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8329 related articles for article (PubMed ID: 2165192)

  • 1. [Expression of nerve growth factor-receptor in normal skin and melanocytic tumor].
    Kageshita T; Nakamura T; Hirai S; Matsuno M; Egawa K; Arao T
    Nihon Hifuka Gakkai Zasshi; 1990 Feb; 100(2):169-73. PubMed ID: 2165192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P75 nerve growth factor receptor staining is superior to S100 in identifying spindle cell and desmoplastic melanoma.
    Lazova R; Tantcheva-Poor I; Sigal AC
    J Am Acad Dermatol; 2010 Nov; 63(5):852-8. PubMed ID: 20950740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.
    Bröcker EB; Magiera H; Herlyn M
    J Invest Dermatol; 1991 May; 96(5):662-5. PubMed ID: 1850772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of neurotrophins and their receptors in pigment cell lesions of the skin.
    Innominato PF; Libbrecht L; van den Oord JJ
    J Pathol; 2001 May; 194(1):95-100. PubMed ID: 11329147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
    Fanburg-Smith JC; Miettinen M
    Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of nerve growth factor receptor in human benign peripheral nerve sheath tumor].
    Yasuda T; Sobue G; Hashizume Y; Mitsuma T; Takahashi A
    Rinsho Shinkeigaku; 1989 Apr; 29(4):411-20. PubMed ID: 2558831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
    Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
    Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
    Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
    Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
    de Vries TJ; Verheijen JH; de Bart AC; Weidle UH; Ruiter DJ; van Muijen GN
    Cancer Res; 1996 Mar; 56(6):1432-9. PubMed ID: 8640836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin.
    Saitoh K; Takahashi H; Sawada N; Parsons PG
    J Pathol; 1994 Nov; 174(3):191-9. PubMed ID: 7823252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
    Giehl KA; Nägele U; Volkenandt M; Berking C
    J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells.
    Sonnenfeld KH; Bernd P; Sobue G; Lebwohl M; Rubenstein AE
    Cancer Res; 1986 Mar; 46(3):1446-52. PubMed ID: 3002618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression.
    Reed JA; Finnerty B; Albino AP
    Am J Pathol; 1999 Aug; 155(2):549-55. PubMed ID: 10433947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma.
    Strömberg S; Agnarsdóttir M; Magnusson K; Rexhepaj E; Bolander A; Lundberg E; Asplund A; Ryan D; Rafferty M; Gallagher WM; Uhlen M; Bergqvist M; Ponten F
    J Proteome Res; 2009 Apr; 8(4):1639-46. PubMed ID: 19714869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 expression in human melanocytes and melanocytic tumors.
    van den Oord JJ; Vandeghinste N; De Ley M; De Wolf-Peeters C
    Am J Pathol; 1994 Aug; 145(2):294-300. PubMed ID: 8053490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
    Montone KT; van Belle P; Elenitsas R; Elder DE
    Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 417.